Home-Based Pharmaceutical Consulting Company, FD-AID, Goes Global in One

Year

A small home-based pharmaceutical consulting company defies the odds and creates a footprint in
three countries in one year. DeVaughn Edwards tells the struggles and successes competing against
massive consulting companies during a pandemic.

Lutz, FL, October 16, 2020 --(PR.com)-- Pharmaceutical consulting companies assist drug manufacturers
remain in or get back into compliance with FDA regulations. On October 01, FD-AID, LLC
Pharmaceutical Consulting celebrated its 1-year anniversary. In a market dominated by huge consulting
agencies, this start-up (initially) home-based company has defied the odds and established a presence in
three countries. FD-AID, LLC Pharma Consulting President, DeVaughn Edwards recently discussed the
challenges of starting a business with such immense competition plus the complexity of starting during a
pandemic. Here's what he had to say.

DE: First, I would like to express my appreciation to all of our clients that gave us the opportunity to
prove how we could provide a better service and product and most importantly, help them succeed.

Q: Well, it looks like you have accomplished a lot in a year. How did you come up with your company
name?

DE: (laughs) I just thought it was clever. When you combine FDA and aid - that summarizes what we do.

Q: Why do you think FD-AID was able to come, I guess, out of the gate with a success story?

DE: Well, we were fortunate to have clients that were willing to try a start-up to resolve some of their
regulatory and compliance issues. To a small degree, we relied on experience with larger consulting
companies to have an impact. For the most part, their business models are similar so client experience and
satisfaction are also common. Expensive marketing campaigns, overwhelming cost/fee structure and
scare tactics to upsell the clients to expand their projects are very common. Their main focus is on
prolonging projects. Their philosophy is ‘the longer we stay, the more they pay.’ I knew that all we
needed was a foot in the door and we could be successful by focusing on providing the best product that
the client has ever received and at the best cost-for-service. We placed our focus on making sure the
client’s problems were resolved in a way nobody else had committed to and that they wanted to work
with us again. We want to see safe drugs in the market place because we all depend on them. Since we
were small, we made sure to develop relationships. Each client is an extension of our family. We
genuinely want success for them and that is a sincere emotion with FD-AID.

Q: Anything else that distinguished your brand?

DE: If there is an edge, I guess it would be the balanced experience between having been an FDA
Investigator and a pharmaceutical executive. I understand what each side needs and have been tested
under some tough conditions on both sides. Most of larger agencies are run by people that have not spent

Page 1/3
PR.com Press Release Distribution Terms of Use
any time at all in an FDA office. They are limited to boardroom experience or they are salespeople with
quotas that they must meet. That experience or lack of experience shows as an indicator when the client’s
problems are not resolved or they get another visit from FDA.

Q: What was the most challenging part about starting your company?

DE: There were many challenges. As you know, with any business there is always going to be a learning
curve whether you are new to the industry or not. You quickly learn that there are incredible people and
incredible companies out there who want you to succeed and will give you a shot. You may also find out
quickly that those who you were anticipating being in your corner dissipate. But, in the long run, that is a
good thing.

Q: Was that your experience? I would think that would be disappointing. What made it a good thing?

DE: Well, it is a matter of perception. FD-AID was able to attract winning companies and have had
measurable success getting them to the next level. Sure, there were some former associates that may have
disappointed us but it was beneficial to know who would stand with you when you need them. It is like a
filter for who should not be in your orbit. I just used it for what good could come of it and incorporated
that into our corporate culture. We will stand with our clients in their darkest moments and get through it
together with them. If evening, weekend or holiday meetings or projects need to be handled, we are there.

Q: So, what other challenges did you have getting off the ground?

DE: Probably the obvious – the situation with the pandemic. This environment limits the face-to-face
client interaction. Not having that interaction was a culture change – replacing an in-person conversation
with Zoom or Microsoft Team meetings. But a lot of the work in the consulting space is auditing. Having
to convert to virtual audits was not a simple process. We just had to make it work. We have completed
audits in various countries and identified a ton of areas for improvement.

Q: Any advice for entrepreneurs that are where you were a year ago?

DE: Sure, I’m a religious person but I will try to keep it general: create a game plan, work your game
plan, be encouraged and don’t allow setbacks to break your spirit. Everything imaginable happened when
we started. Cars broke down, various bills popped up depleting capital, you name it. I was even in China
right before the pandemic trying to get things going and it was a disaster story all on its own. This is what
stops most people from being successful. It gets overwhelming and they give up. Don’t give up.

DeVaughn Edwards is a former FDA Investigator, Pharma executive and author. FD-AID is a Florida
based consulting company and is online at: http://fdaid.org

Page 2/3
PR.com Press Release Distribution Terms of Use
Contact Information:
FD-AID, LLC
DeVaughn Edwards
732-895-7831
Contact via Email
http://fdaid.org
devaughn@gmail.com

Online Version of Press Release:

You can read the online version of this press release at: https://www.pr.com/press-release/823514

News Image:

Page 3/3
PR.com Press Release Distribution Terms of Use